Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Epacadostat (INCB024360) With Pembrolizumab (MK3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired Biopsies

NCT03196232 is registered in ClinicalTrials.gov with George Albert Fisher as lead sponsor.

NCT NCT03196232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03196232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Epacadostat (INCB024360) With Pembrolizumab (MK3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired Biopsies
Lead sponsor
George Albert Fisher
Phase
Phase 2
Overall status
Completed
Start date
September 13, 2017
Completion date
May 29, 2018
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, recurrent esophageal carcinoma, recurrent gastric carcinoma, stage iv esophageal cancer ajcc v7, stage iv gastric cancer ajcc v7, unresectable esophageal carcinoma